立体定向放射治疗技术在小肝癌中的应用

刘文君; 杜丹; 陈宝杰; 姚婷; 李贤富

doi:10.3969/j.issn.1001-5256.2021.05.050

立体定向放射治疗技术在小肝癌中的应用

DOI: 10.3969/j.issn.1001-5256.2021.05.050

川北医学院附属医院放疗科，四川南充 637000

基金项目:

四川省教育厅自然科学重点项目 (17ZA0173)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：刘文君复杂资料收集、分析，撰写论文，修改论文；杜丹、陈宝杰、姚婷负责参与收集、分析、讨论资料，修改论文；李贤富负责课题设计，拟定写作思路，指导撰写文章并最后定稿。

详细信息

作者简介:
刘文君(1992—)，男，主要从事肿瘤临床研究

通信作者:
李贤富，lixianfu13@163.com

中图分类号: R735.7
计量
- 文章访问数: 411
- HTML全文浏览量: 304
- PDF下载量: 37
- 被引次数: 0
出版历程
- 收稿日期: 2020-10-08
- 录用日期: 2020-11-09
- 出版日期: 2021-05-20

Application of stereotactic body radiotherapy in small hepatocellular carcinoma

Department of Radiotherapy, Affiliated Hospital of Chuanbei Medical College, Nanchong, Sichuan 637000, China

摘要

摘要: 目前手术切除(HR)和射频消融(RFA)是小肝癌的主要根治性治疗手段，而立体定向放射治疗(SBRT)技术发展迅速，SBRT有效治疗小肝癌的研究报道不断增多。介绍了SBRT治疗小肝癌的技术优势、放射治疗剂量及分割模式、正常肝组织限量与周边危及器官的保护；分别比较了SBRT与HR、RFA治疗小肝癌的疗效；简述了SBRT治疗小肝癌不良反应。已有的研究表明，对于某些小肝癌，SBRT在疗效方面不亚于甚至优于HR和RFA，毒性可控，SBRT有望成为小肝癌的另一种根治性方式。
- 肝肿瘤 /
- 放射外科手术 /
- 放射治疗剂量 /
- 治疗结果
Abstract: At present, hepatic resection (HR) and radiofrequency ablation of (RFA) are the main radical treatment methods for small hepatocellular carcinoma (sHCC), while stereotactic body radiotherapy (SBRT) is developing rapidly and there is an increasing number of reports on the effective treatment of sHCC with SBRT. This article introduces the technical advantages, therapeutic dose, and fractionation scheme of SBRT in the treatment of sHCC, as well as the limit of normal liver tissue and the protection of surrounding organs at risk. This article also compares the efficacy of SBRT versus HR and RFA in the treatment of sHCC and briefly describes the adverse reactions of SBRT in the treatment of sHCC. Previous studies have shown that for some sHCC cases, SBRT has an equal or even better clinical effect than HR and RFA, with controllable toxicity. Therefore, SBRT is expected to become another radical treatment method for sHCC.
- Liver Neoplasms /
- Radiosurgery /
- Radiotherapy Dosage /
- Treatment Outcome

HTML全文

参考文献(35)

[1]	GE WL. Prognostic analysis of regular or irregular hepatectomy for single small hepatocellular carcinoma[J]. J Hepatobiliary Surg, 2017, 25 (3): 181-185. DOI: 10.3969/j.issn.1006-4761.2017.03.007. 葛万灵. 规则性或非规则性肝癌切除术治疗单发小肝癌的预后分析[J]. 肝胆外科杂志, 2017, 25(3): 181-185. DOI: 10.3969/j.issn.1006-4761.2017.03.007.
[2]	HE J, MAO YS, SHEN K, et al. Clinical Oncology[M]. Beijing: People's Health publishing house, 2016: 450. (in Chinese) 赫捷, 毛友生, 沈铿, 等. 临床肿瘤学[M]. 北京: 人民卫生出版社, 2016: 450.
[3]	Medical Administration of the National Health Commission of the people's Republic of China. Standard for diagnosis and treatment of primary liver cancer (2019 Edition)[J]. J Clin Hepatol, 2020, 36 (2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007. 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
[4]	JEONG Y, JUNG J, CHO B, et al. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma[J]. BMC Cancer, 2018, 18(1): 416. DOI: 10.1186/s12885-018-4340-7.
[5]	ZENG ZC, SUN JG, LANG JY. Radiotherapy for hepatocellular carcinoma downstaging: From palliative care to radical treatment[J]. J Clin Hepatol, 2020, 36(2): 258-262. DOI: 10.3969/j.issn.1001-5256.2020.02.003. 曾昭冲, 孙建国, 郎锦义. 肝细胞癌放疗降期——从姑息走向根治[J]. 临床肝胆病杂志, 2020, 36(2): 258-262. DOI: 10.3969/j.issn.1001-5256.2020.02.003.
[6]	ZENG ZC. Stereotactic radiotherapy for liver cancer is a radical method worth exploring[J]. Liver, 2020, 25(7): 665-667. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN202007005.htm 曾昭冲. 肝癌立体定向放疗是值得探索的根治性方法[J]. 肝脏, 2020, 25(7): 665- 667. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN202007005.htm
[7]	ZENG ZC, SEONG J, YOON SM, et al. Consensus on stereotactic body radiation therapy for small-sized hepatocellular carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting[J]. Liver Cancer, 2017, 6(4): 264-274. DOI: 10.1159/000475768.
[8]	WANG PM, HSU WC, CHUNG NN, et al. Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients[J]. Radiat Oncol, 2014, 9: 18. DOI: 10.1186/1748-717X-9-18.
[9]	ZHANG T, SUN J, HE WP, et al. Clinical effect of CyberKnife stereotactic radiosurgery in treatment of patients with small hepatocellular carcinoma[J]. J Clin Hepatol, 2017, 33(4): 694-698. DOI: 10.3969/j.issn.1001-5256.2017.04.019. 张弢, 孙静, 何卫平, 等. 射波刀立体定向放射治疗小肝癌的临床效果[J]. 临床肝胆病杂志, 2017, 33(4): 694-698. DOI: 10.3969/j.issn.1001-5256.2017.04.019.
[10]	JIN H, CHALKIDOU A, HAWKINS M, et al. Cost-effectiveness analysis of stereotactic ablative body radiation therapy compared with surgery and radiofrequency ablation in two patient cohorts: Metastatic liver cancer and hepatocellular carcinoma[J]. Clin Oncol (R Coll Radiol), 2021, 33(3): e143-e154. DOI: 10.1016/j.clon.2020.08.010.
[11]	LU L, DIACONU C, DJEMIL T, et al. Intra- and inter-fractional liver and lung tumor motions treated with SBRT under active breathing control[J]. J Appl Clin Med Phys, 2018, 19(1): 39-45. DOI: 10.1002/acm2.12220.
[12]	HU Y, ZHOU YK, CHEN YX, et al. 4D-CT scans reveal reduced magnitude of respiratory liver motion achieved by different abdominal compression plate positions in patients with intrahepatic tumors undergoing helical tomotherapy[J]. Med Phys, 2016, 43(7): 4335. DOI: 10.1118/1.4953190.
[13]	CHEN YX, ZHUANG Y, YANG P, et al. Helical IMRT-based stereotactic body radiation therapy using an abdominal compression technique and modified fractionation regimen for small hepatocellular carcinoma[J]. Technol Cancer Res Treat, 2020, 19: 1533033820937002. DOI: 10.1177/1533033820937002.
[14]	YOON SM, KIM SY, LIM YS, et al. Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase Ⅱ clinical trial[J]. Clin Mol Hepatol, 2020, 26(4): 506-515. DOI: 10.3350/cmh.2020.0038.
[15]	GKIKA E, TANADINI-LANG S, KIRSTE S, et al. Interobserver variability in target volume delineation of hepatocellular carcinoma: An analysis of the working group "Stereotactic Radiotherapy" of the German Society for Radiation Oncology (DEGRO)[J]. Strahlenther Onkol, 2017, 193(10): 823-830. DOI: 10.1007/s00066-017-1177-y.
[16]	SHETH N, OSBORN V, LEE A, et al. Stereotactic ablative radiotherapy fractionation for hepatocellular carcinoma in the United States[J]. Cureus, 2020, 12(6): e8675. DOI: 10.7759/cureus.8675.
[17]	PARK HC, SEONG J, HAN KH, et al. Dose-response relationship in local radiotherapy for hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2002, 54(1): 150-155. DOI: 10.1016/s0360-3016(02)02864-x.
[18]	SUN J, ZHANG T, WANG J, et al. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm)[J]. BMC Cancer, 2019, 19(1): 846. DOI: 10.1186/s12885-019-6063-9.
[19]	PARK S, JUNG J, CHO B, et al. Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2020, 35(11): 1953-1959. DOI: 10.1111/jgh.15011.
[20]	OHRI N, TOMÉ WA, MÉNDEZ ROMERO A, et al. Local control after stereotactic body radiation therapy for liver tumors[J]. Int J Radiat Oncol Biol Phys, 2018. DOI: 10.1016/j.ijrobp.2017.12.288.
[21]	GUHA C, KAVANAGH BD. Hepatic radiation toxicity: Avoidance and amelioration[J]. Semin Radiat Oncol, 2011, 21(4): 256-263. DOI: 10.1016/j.semradonc.2011.05.003.
[22]	JUNG J, YOON SM, KIM SY, et al. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: Clinical and dose-volumetric parameters[J]. Radiat Oncol, 2013, 8: 249. DOI: 10.1186/1748-717X-8-249.
[23]	SON SH, CHOI BO, RYU MR, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: Dose-volumetric parameters predicting the hepatic complication[J]. Int J Radiat Oncol Biol Phys, 2010, 78(4): 1073-1080. DOI: 10.1016/j.ijrobp.2009.09.009.
[24]	SU TS, LIANG P, LU HZ, et al. Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients[J]. J Surg Oncol, 2016, 113(2): 181-187. DOI: 10.1002/jso.24128.
[25]	MOORE A, COHEN-NAFTALY M, TOBAR A, et al. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable hepatocellular carcinoma[J]. Radiat Oncol, 2017, 12(1): 163. DOI: 10.1186/s13014-017-0899-4.
[26]	KUBO K, KIMURA T, AIKATA H, et al. Long-term outcome of stereotactic body radiotherapy for patients with small hepatocellular carcinoma[J]. Hepatol Res, 2018, 48(9): 701-707. DOI: 10.1111/hepr.13063.
[27]	SU TS, LIANG P, LIANG J, et al. Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2017, 98(3): 639-646. DOI: 10.1016/j.ijrobp.2017.02.095.
[28]	SUN J, WANG Q, HONG ZX, et al. Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤5 cm): A propensity score analysis[J]. Hepatol Int, 2020, 14(5): 788-797. DOI: 10.1007/s12072-020-10088-0.
[29]	SEO YS, KIM MS, YOO HJ, et al. Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: A Markov model-based analysis[J]. Cancer Med, 2016, 5(11): 3094-3101. DOI: 10.1002/cam4.893.
[30]	WAHL DR, STENMARK MH, TAO Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma[J]. J Clin Oncol, 2016, 34(5): 452-459. DOI: 10.1200/JCO.2015.61.4925.
[31]	KIM N, CHENG J, JUNG I, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma[J]. J Hepatol, 2020, 73(1): 121-129. DOI: 10.1016/j.jhep.2020.03.005.
[32]	PAN CC, KAVANAGH BD, DAWSON LA, et al. Radiation-associated liver injury[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl): s94-s100. DOI: 10.1016/j.ijrobp.2009.06.092.
[33]	BAUMANN BC, WEI J, PLASTARAS JP, et al. Stereotactic Body Radiation Therapy (SBRT) for hepatocellular carcinoma: High rates of local control with low toxicity[J]. Am J Clin Oncol, 2018, 41(11): 1118-1124. DOI: 10.1097/COC.0000000000000435.
[34]	KIM JW, SEONG J, LEE IJ, et al. Phase Ⅰ dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma[J]. Oncotarget, 2016, 7(26): 40756-40766. DOI: 10.18632/oncotarget.9450.
[35]	DOBRZYCKA M, SPYCHALSKI P, ROSTKOWSKA O, et al. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome[J]. Acta Oncol, 2019, 58(12): 1706-1713. DOI: 10.1080/0284186X.2019.1657942.